How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story
Collegium Pharmaceutical reported strong Q1 2026 net income and reaffirmed its full-year product revenue guidance, signaling continued commercial momentum. However, upcoming departures of its Chief Commercial Officer and Chief Medical Officer introduce potential execution risks. The article examines how these events impact Collegium's investment narrative, particularly concerning its pain and ADHD drug portfolio and upcoming patent expirations.
COLL: Consistent 2026 Earnings Guidance Will Support Affordable Medicines Theme Upside
Collegium Pharmaceutical's fair value has been slightly increased by analysts, moving from $54.17 to $54.33, driven by updated assumptions in revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance for product revenues, net, in the range of $805 million to $825 million, emphasizing consistency in its outlook. Additionally, Collegium Pharmaceutical reported no share repurchases in late 2025 and early 2026 and announced a multi-year partnership with Boston Legacy FC.
Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952
Collegium Pharmaceutical director John Gordon Freund reported selling 20 common shares at $34.05 each on May 18, 2026, in an open-market transaction. Following this sale, he directly holds 83,952 common shares and also has indirect interests in additional shares through affiliated entities. The Form 4 filing details his direct and indirect holdings, emphasizing that his beneficial ownership for indirect shares is limited to his proportionate pecuniary interest.
Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL)
Collegium Pharmaceutical director Nancy Lurker was granted 8,741 restricted stock units (RSUs) as part of her compensation, with each RSU representing one share of common stock. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 annual shareholder meeting, contingent on her continued service. Following this award, Lurker's direct holdings in Collegium Pharmaceutical total 26,758 shares.
Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award
Collegium director Rita J. Balice-Gordon was granted 8,741 Restricted Stock Units (RSUs), increasing her direct holdings to 61,370 shares. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, provided she continues her service as a director. The grant, detailed in a Form 4 filing, is a form of equity compensation.
Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3
Collegium Pharmaceutical (COLL) director Donovan Michael Glancy has filed an initial Form 3, indicating his start as a reporting person for the company. This filing discloses his initial ownership of Collegium Pharmaceutical securities but does not report any transactions or derivative positions. A Form 3 is a mandatory SEC filing for new insiders, establishing a baseline for their holdings.
Collegium (COLL) director sells shares, exercises options and receives RSU grant
Collegium Pharmaceutical director John Gordon Freund recently sold 4,127 shares of common stock, exercised options for 8,700 shares, and received a grant of 8,741 restricted stock units (RSUs). After these transactions, his direct holdings stand at 83,972 shares, with additional indirect holdings through family partnerships and investment firms. The RSUs are set to vest by May 14, 2027, or the company's 2027 annual meeting, contingent on his continued board service.
Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant
Collegium Pharmaceutical director Gino Santini was granted 8,741 restricted stock units (RSUs) on May 14, 2026, as an equity award with a $0.00 purchase price. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, provided he continues his service as a director. Following this grant, Santini directly holds 103,783 shares of Collegium common stock, illustrating a form of compensation tied to continued service and company performance.
Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL)
COLLEGIUM PHARMACEUTICAL, INC. director Carlos V. Paya was granted 8,741 restricted stock units (RSUs) as compensation, increasing his direct holdings to 28,323 shares. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, contingent on his continued board service. The grant price was $0.00, and the settlement will be in common stock shares upon vesting or under specific conditions like the end of his board service or a change in control.
Collegium Pharmaceutical (COLL) director receives 8,741 RSU grant, now holds 71,000 shares
Collegium Pharmaceutical director Garen G. Bohlin was granted 8,741 Restricted Stock Units (RSUs), increasing his direct holdings to 71,000 shares. These RSUs, which represent one share of common stock each, will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, contingent on his continued board service. The grant was a compensation-related award with no cash purchase involved.
Director at Collegium (COLL) awarded 17,482 restricted stock units
Collegium Pharmaceutical director Michael Glancy was granted 17,482 restricted stock units (RSUs) on May 14, 2026, at no cash cost. These RSUs will vest in two equal tranches on or around May 14, 2027, contingent on his continued service to the board. Following this grant, Glancy holds 17,482 shares.
Collegium pharmaceutical director sells $142k in shares
A director at Collegium Pharmaceutical, John Gordon Freund, recently sold shares worth $142,546 and exercised stock options on May 14 and 15, 2026. Despite the stock being down 27% year-to-date, it has risen 12% over the past year. The company also reported strong Q1 2026 financial results with EPS of $1.76 and revenue of $193.5 million, surpassing analyst expectations.
Have Collegium Pharmaceutical Insiders Been Selling Stock?
Collegium Pharmaceutical (NASDAQ:COLL) has seen recent insider selling, including a notable divestment of US$162k by Independent Director Nancy Lurker, representing 20% of her holding. Over the last year, the Executive VP & Chief Medical Officer, Thomas Smith, also sold US$672k worth of shares, though at a price higher than the current market value. Despite these sales, the article notes that insider ownership still stands at 1.1% of the company, valued at approximately US$12 million.
Collegium Pharmaceutical stock (US19459E1029): opioid-pain specialist in focus after Q1 2026 earning
Collegium Pharmaceutical, a U.S.-focused specialty pharmaceutical company, is in the spotlight following its Q1 2026 earnings report, reaffirming its commitment to chronic pain medicines. The company's business model centers on extended-release opioid formulations, navigating strict prescribing rules and payer relationships in the U.S. market. Its revenue drivers, competitive position, and the broader trends in opioid regulation are crucial factors for investors to consider.
[SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment Disclosure
COLLEGIUM PHARMACEUTICAL, INC. has filed an amended Schedule 13G/A disclosing that Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D. and Robin C. John, beneficially own 1,424,282 shares, representing 4.5% of the company's common stock. Eventide has sole voting and dispositive power over these shares, while Kuruvilla and John report shared voting and dispositive power. The filing notes this is a passive investment, with the filers disclaiming beneficial ownership under Rule 13d-4.
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing
This SEC filing is a Form 144 Notice of Proposed Sale of Securities for COLLEGIUM PHARMACEUTICAL, INC (COLL). The filing indicates an intent to sell 4127 shares of common stock with an aggregate market value of $142,546.99, acquired via an option granted in 2016. The proposed sale date is May 15, 2026, through Fidelity Brokerage Services LLC on NASDAQ.
Collegium (NASDAQ: COLL) shareholders back board, pay and auditor at 2026 meeting
Collegium Pharmaceutical, Inc. shareholders approved all proposals at their 2026 Annual Meeting, including the election of eight directors, the advisory approval of named executive officer compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A total of 29,210,926 shares were represented at the meeting out of 32,406,969 eligible shares.
Collegium Pharmaceutical (COLL) director sells 4,500 shares in market trade
Collegium Pharmaceutical director Nancy Lurker sold 4,500 shares of common stock on May 13, 2026, at a weighted average price of $35.9691 per share, totaling $161,861. After this open-market transaction, she directly holds 18,017 shares. The sale reinforces transparency regarding insider trading activities as reported in a Form 4 filing.
Janus Henderson (COLL) reports 1.83M-share, 5.8% holding in PHARMACEUTICAL, INC.
Janus Henderson Group plc, through its Asset Managers, has disclosed a beneficial ownership of 1,825,651 shares, or 5.8% of the common stock, in Collegium Pharmaceutical, Inc. as of March 31, 2026. Filed as a Schedule 13G, this indicates a passive investment where the Asset Managers exercise shared voting and dispositive power on behalf of managed portfolios, disclaiming direct economic rights to dividends or sale proceeds. The filing specifies that the managed portfolios retain economic rights, and no single portfolio owns more than five percent of Collegium Pharmaceutical, Inc.
Renaissance files 4.53% holding in PHARMACEUTICAL, INC (COLL)
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed an amended Schedule 13G/A, disclosing a 4.53% passive stake in COLLEGIUM PHARMACEUTICAL, INC (COLL). This equates to 1,469,449 shares of common stock, over which they maintain sole voting and dispositive power. The filing, dated May 14, 2026, indicates this ownership is for investment purposes and not intended to influence control of the company.
Statutory Profit Doesn't Reflect How Good Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are
Collegium Pharmaceutical's recent strong earnings were not fully reflected in its stock price reaction due to underlying factors. The company's negative accrual ratio of -0.28 indicates excellent cash conversion, with free cash flow significantly exceeding reported profit. Additionally, unusual items reduced statutory profit by US$27m, suggesting that actual earnings potential may be understated.
Collegium (NASDAQ: COLL) director exercises options, sells 8,700 shares at $37
Collegium Pharmaceutical director Garen G. Bohlin exercised stock options for 8,700 shares at $16.49 each and subsequently sold these shares on the open market at a weighted average price of $37.1829. These transactions took place on May 11, 2026, and after the sale, Bohlin directly holds 62,259 shares of the company's common stock, with the exercised option position reduced to zero.
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing
This article details a Form 144 SEC filing by COLLEGIUM PHARMACEUTICAL, INC (COLL) on May 13, 2026, pertaining to the proposed sale of 4,500 shares of common stock with an aggregate market value of $161,861.16. The shares were acquired on February 4, 2026, through restricted stock vesting. The filing indicates the securities are to be sold through Fidelity Brokerage Services LLC on NASDAQ.
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Pharmaceutical, Inc. has completed the acquisition of AZSTARYS® from Corium Therapeutics, expanding its ADHD portfolio and raising its 2026 financial guidance. The acquisition, valued at approximately $650 million, strengthens Collegium's position in the ADHD market and is expected to be immediately accretive to its financial performance. The company projects total product revenues between $865 to $895 million and adjusted EBITDA of $475 to $500 million for 2026.
A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed
Collegium Pharmaceutical (COLL) is garnering attention after reporting strong Q1 2026 earnings and proposing an AZSTARYS acquisition, despite mixed recent share price performance. The company is considered undervalued by its most popular valuation narrative, with a fair value of $54.17 against a last close of $37.80, driven by margin expansion and growth in its specialty pharmaceutical portfolio. However, the valuation relies on optimistic margin assumptions and faces potential risks from patent expiries.
[SCHEDULE 13G] COLLEGIUM PHARMACEUTICAL, INC Passive Investment Disclosure (>5%)
A Schedule 13G filing for Collegium Pharmaceutical, Inc. (COLL) reveals that a group of investors, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, reported shared beneficial ownership of approximately 4.7% of common stock. These entities briefly exceeded a 5% ownership threshold on May 7, 2026, but subsequently reported that they ceased to be beneficial owners of more than 5% by the filing date. The filing details shared voting and dispositive powers for 1,515,406 and 1,519,500 shares, respectively, and includes a Joint Filing Agreement dated May 11, 2026.
Collegium Pharmaceutical Completes AZSTARYS ADHD Business Acquisition
Collegium Pharmaceutical has completed its $650 million acquisition of the AZSTARYS ADHD business from Corium Therapeutics, enhancing its ADHD portfolio. This acquisition led to updated 2026 guidance, projecting increased net product revenues and adjusted EBITDA, along with significant annual synergies. The company also announced an inducement equity plan and upcoming executive departures as it integrates the new business.
AZSTARYS deal lifts Collegium (NASDAQ: COLL) 2026 revenue and EBITDA outlook
Collegium Pharmaceutical (NASDAQ: COLL) has completed the acquisition of AZSTARYS, an ADHD CNS stimulant, for approximately $650 million. This acquisition has led Collegium to raise its 2026 financial guidance, projecting higher total product revenues and adjusted EBITDA. The company expects significant revenue contribution from AZSTARYS and anticipates over $50 million in annual run-rate synergies.
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Pharmaceutical, Inc. has completed the acquisition of AZSTARYS® from Corium Therapeutics, expanding its ADHD portfolio. This acquisition is expected to add $60 to $70 million in net revenue for the remainder of 2026 and extends patent protection through 2037. Consequently, Collegium has raised its 2026 financial guidance, anticipating total product revenues between $865 to $895 million and adjusted EBITDA between $475 to $500 million.
Collegium Pharmaceutical, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:COLL) 2026-05-11
Collegium Pharmaceutical, Inc. (COLL) released its Q1 2026 earnings, reporting an EPS of $1.76, beating estimates by $0.24, and revenue of $193.52 million, surpassing expectations by $9.06 million, representing an 8.87% year-over-year increase. The company published a slide deck in conjunction with its earnings call. This presentation provides detailed insights into the financial performance for the quarter.
COLLEGIUM PHARMACEUTICAL, INC SEC Filing
This article reports on a Form 144 SEC filing by Collegium Pharmaceutical, Inc. (COLL) dated May 11, 2026. The filing indicates a proposed sale of 8,700 shares of common stock with an aggregate market value of $323,491.00 through Fidelity Brokerage Services, acquired via an option granted on June 9, 2016.
A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed
Collegium Pharmaceutical (COLL) recently reported strong first-quarter 2026 earnings, showing increased profitability and progress in ADHD and pain product lines, complemented by a proposed AZSTARYS acquisition. Despite positive long-term shareholder returns, its recent share performance has been mixed. The company is considered undervalued by analysis, with a fair value around $54.17 compared to its current price of $37.80, driven by anticipated margin expansion and disciplined capital use.
Collegium Pharmaceutical (COLL) Earnings Growth Far Outpaces Revenue And Tests Cautious Narratives
Collegium Pharmaceutical (COLL) reported strong Q1 2026 earnings per share (EPS) of US$0.45, with a significant 70.8% earnings growth over the last year, largely outpacing its 4.3% revenue increase. While the company's net margin improved to 9.4%, a US$30.2 million one-off loss in the trailing twelve months creates a mixed picture for investors. The stock's current P/E of 17x is near the industry average but analysts and DCF models suggest significant upside.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2026 Earnings Call Transcript
Collegium Pharmaceutical (NASDAQ: COLL) reported strong Q1 2026 earnings, beating expectations with an EPS of $1.76 against an anticipated $1.52. The company highlighted significant progress in its strategic priorities, including the proposed acquisition of AZSTARYS to strengthen its ADHD portfolio and continued growth of JORNAY PM and its pain portfolio. Collegium reiterated its 2026 financial guidance for its existing business and expects the AZSTARYS acquisition to be immediately accretive to adjusted EBITDA, extending revenue longevity and generating substantial cost synergies.
Collegium Pharmaceutical (COLL) Earnings Growth Far Outpaces Revenue And Tests Cautious Narratives
Collegium Pharmaceutical (COLL) reported impressive Q1 2026 results, with earnings growth significantly outpacing revenue, indicating improved profitability. Despite concerns over revenue growth being below the wider US market and a notable one-off loss, the company's P/E ratio is near the industry average, yet a Discounted Cash Flow (DCF) fair value suggests significant undervaluation. This performance challenges some cautious narratives, presenting a mixed picture of risk and reward for investors.
Collegium Pharmaceutical (COLL) Earnings Growth Far Outpaces Revenue And Tests Cautious Narratives
Collegium Pharmaceutical (COLL) reported strong Q1 2026 results with a 70.8% earnings growth, significantly outpacing its 4.3% revenue rise. This performance has led to a 9.4% net margin, despite a one-off loss of US$30.2 million. The stock currently trades at a P/E of 17x, which is near the US Pharmaceuticals average, but analysts and DCF models suggest a much higher fair value, sparking conversations about whether its recent profitability justifies a re-evaluation by investors.
Collegium Pharma Expects to Update 2026 Guidance Following Close of AZSTARYS Acquisition >COLL
Collegium Pharmaceutical Inc. (COLL) anticipates revising its 2026 financial guidance after the completion of its acquisition of the AZSTARYS license and related assets. The acquisition is expected to close by the end of Q3 2026, and the updated guidance will reflect the financial impact of this transaction as the company integrates the new assets into its portfolio.
Collegium Reports Strong Q1 Results, Reaffirms 2026 Outlook
Collegium Pharmaceutical (COLL) announced strong first-quarter 2026 results, with net product revenue growing 9% to $193.5 million, driven by significant growth in JORNAY PM and its pain portfolio. The company reported $14.5 million in GAAP net income and $103.9 million in adjusted EBITDA. Collegium also reaffirmed its full-year 2026 guidance and is advancing its ADHD strategy with the planned acquisition of AZSTARYS.
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical, Inc. reported strong first-quarter 2026 financial results, with net revenues up 9% year-over-year to $193.5 million. The company showcased significant growth in its ADHD portfolio, particularly with JORNAY PM, and announced the impending acquisition of AZSTARYS, expected to close in Q2 2026. Collegium reaffirmed its full-year 2026 financial guidance for its current business and highlighted robust performance across its pain management portfolio.
Collegium (NASDAQ: COLL) lifts Q1 2026 profit and inks $650M AZSTARYS deal
Collegium Pharmaceutical (NASDAQ: COLL) reported significant financial improvements in Q1 2026, with net income surging to $14.5 million from $2.4 million year-over-year, and diluted EPS reaching $0.40. Product revenues, net, rose to $193.5 million, driven by strong growth in Belbuca, Xtampza ER, Jornay PM, and Symproic. Additionally, Collegium announced an agreement to acquire AZSTARYS for $650 million in cash plus up to $135 million in milestones, aiming to expand its neuropsychiatry portfolio, with funding planned from existing cash and a delayed draw term loan.
Collegium (NASDAQ: COLL) posts Q1 2026 growth and plans accretive AZSTARYS ADHD deal
Collegium Pharmaceutical (NASDAQ: COLL) reported strong Q1 2026 results with product revenues up 9% year-over-year, driven by a 36% increase in JORNAY PM revenue. The company reaffirmed its full-year 2026 guidance and announced the planned acquisition of AZSTARYS for $650 million cash plus potential milestones, which is expected to be immediately accretive to adjusted EBITDA and strengthen its ADHD portfolio. Collegium ended the quarter with $421.8 million in cash and generated $57.1 million in operating cash flow, supporting its growth strategies and capital deployment.
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical, Inc. announced strong first-quarter 2026 financial results, with net revenues up 9% year-over-year and JORNAY PM® net revenue increasing by 36%. The company is on track to close the acquisition of AZSTARYS® in the second quarter, which is expected to strengthen its ADHD portfolio. Collegium reaffirmed its full-year 2026 guidance for its current business, excluding the impact of the AZSTARYS acquisition.
Collegium Pharmaceutical: Q1 Earnings Snapshot
Collegium Pharmaceutical Inc. (COLL) reported a first-quarter profit of $14.5 million, or 40 cents per share. Adjusted earnings for the specialty pharmaceutical company were $1.76 per share, with revenue reaching $193.5 million for the period.
What Collegium Pharmaceutical (COLL)'s Margin Pressure Ahead of Q1 2026 Earnings Means For Shareholders
Collegium Pharmaceutical (COLL) is facing investor scrutiny over shrinking adjusted operating margins and its relatively small revenue base as it approaches its Q1 2026 earnings release. While the company reaffirmed its 2026 net product revenue guidance, the market will be looking for management’s commentary on margin sustainability and cost discipline. Despite mixed fair value estimates from the Simply Wall St Community, potential concerns about profitability persist.
Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For
Collegium Pharmaceutical (COLL) is set to announce its Q1 earnings this Thursday. The company is expected to report 3.8% year-on-year revenue growth, a slowdown from the previous year. Analysts have largely reconfirmed their estimates, and the stock has seen positive sentiment in the branded pharmaceuticals segment, trading above its average analyst price target.
Small-Cap Stock Analysis: Tetra Tech Highlighted, Macy's and Collegium Pharmaceutical Flagged - News and Statistics
This article identifies one small-cap stock, Tetra Tech (NASDAQ: TTEK), as a potential investment opportunity due to its robust services in environmental solutions and sustainable infrastructure. Conversely, Macy's (NYSE: M) and Collegium Pharmaceutical (NASDAQ: COLL) are flagged as "sells" because of declining sales, rising costs, and eroding returns. The analysis highlights the importance of distinguishing long-term winners from losers among small-cap companies, which Wall Street often overlooks.
Is Collegium Pharmaceutical (COLL) Offering A Valuation Opportunity After Recent Share Price Weakness
Collegium Pharmaceutical (COLL) has seen recent share price weakness, with a 24.6% decline year-to-date. However, a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 81.4%, with an intrinsic value of $184.04 per share compared to its current price of $34.32. Additionally, the company's P/E ratio of 17.69x is below Simply Wall St's proprietary Fair Ratio of 23.74x, further indicating a potential valuation opportunity.
Is Collegium Pharmaceutical (COLL) Offering A Valuation Opportunity After Recent Share Price Weakness
Collegium Pharmaceutical (COLL) has seen mixed stock performance recently, with a 24.6% decline year-to-date. A Discounted Cash Flow (DCF) analysis suggests the stock is 81.4% undervalued, with an intrinsic value of $184.04 per share compared to its current price of $34.32. Additionally, its P/E ratio of 17.69x is below its Fair Ratio of 23.74x, further indicating it may be trading at a discount.
Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday
Collegium Pharmaceutical (COLL) is set to release its Q1 2026 earnings before market open on Thursday, May 7th, with analysts forecasting EPS of $1.69 and revenue of $187.36 million. The company missed Q4 2025 estimates and two executive VPs recently sold significant shares. Despite some analyst downgrades, COLL holds a "Moderate Buy" consensus rating with an average price target of $53.40, currently trading around $33.76.
Understanding the Setup: (COLL) and Scalable Risk
This article provides an analysis of Collegium Pharmaceutical Inc. (NASDAQ: COLL) using AI models to define trading strategies and risk parameters. It highlights positive near-term sentiment but a weak mid-term bias within a long-term strength context. The analysis includes institutional trading strategies for different risk profiles, multi-timeframe signal analysis, and AI-generated support and resistance levels.
